Sebastian Inger active positions
Companies | Position | Start | End |
---|---|---|---|
NBCD A/S
NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | Director/Board Member | - | - |
Career history of Sebastian Inger
Statistics
International
Denmark | 2 |
Operational
Director/Board Member | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
NBCD A/S
NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | Health Technology |
- Stock Market
- Insiders
- Sebastian Inger
- Experience